| P50 | author | Ana Herranz-Alonso | Q61372837 |
| | José Luis Revuelta-Herrero | Q88840763 |
| P2093 | author name string | Roberto Alonso | |
| | María Sanjurjo-Sáez | |
| | Esther Chamorro-de-Vega | |
| | Carmen Guadalupe Rodríguez-González | |
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort | Q28552719 |
| | A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 |
| | Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data | Q30851182 |
| | Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States | Q34181784 |
| | Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients | Q36684156 |
| | Better adherence with once-daily antiretroviral regimens: a meta-analysis | Q37255897 |
| | Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. | Q37263531 |
| | Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials | Q37696578 |
| | Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients | Q38915213 |
| | Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice | Q39204914 |
| | Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients | Q40446339 |
| | Once daily dosing improves adherence to antiretroviral therapy. | Q46065788 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dolutegravir | Q937224 |
| P304 | page(s) | 11-18 | |
| P577 | publication date | 2017-08-24 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients | |
| P478 | volume | 52 | |